Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-41

While uncertainty is the key word for markets currently, this time will pass and those that are brave and have funds to match that will capitalise on that FUD.
While Imugene have some time to go before they are a Risk off proposition, they certainly are well ahead of many other bio stocks in Australia.
Some of the current stocks while 3,4&5 times Imugene's share price, they have nowhere near the value in IP or trial results.
Imugene appears to be a little sleeper, quietly going about what they do best and trying not to be distracted by the sp debate noise, this can be difficult given that is a singular thought for many of their shareholders.
I hope that sanity prevails at the AGM, and that the BOD and management are supported in their continuing drive for better results.
That is not to say that I believe hard questions shouldn't be asked as accountability is crucial to this debate.
Results will come, not this year, possibly late next year or early 2025, that is not a long time in investment terms and if shareholders are able to hold on for this period, we could possibly see a share price many multiples of today's.

DYOR opinion only